

Table 1 GCC-LC/MS を用いた PA 単糖分析における PA 糖鎖安定同位体の影響

		SIM ion intensity (peak area ratio %) derived from d ₀ -PA and d ₄ -PA-monosaccharides											
Ion (<i>m/z</i>)	d ₀ PA-Fuc	d ₄ PA-Fuc	d ₀ PA-Gal	d ₄ PA-Gal	d ₀ PA-Man	d ₄ PA-Man	d ₀ PA-Glc	d ₄ PA-Glc	d ₀ PA-GlcNAc	d ₄ PA-GlcNAc	d ₀ PA-GalNAc	d ₄ PA-GalNAc	
243	86.6	-	-	-	-	-	-	-	-	-	-	-	
244	11.7	-	-	-	-	-	-	-	-	-	-	-	
245	1.7	0.7	-	-	-	-	-	-	-	-	-	-	
246	-	4.6	-	-	-	-	-	-	-	-	-	-	
247	-	82.6	-	-	-	-	-	-	-	-	-	-	
248	-	10.4	-	-	-	-	-	-	-	-	-	-	
249	-	1.7	-	-	-	-	-	-	-	-	-	-	
259	-	-	87.4	-	88.6	-	87.6	-	-	-	86.0	-	
260	-	-	11.0	-	9.9	-	11.1	-	-	-	12.3	-	
261	-	1.6	1.6	0.7	1.5	0.4	1.3	0.8	-	-	1.7	0.5	
262	-	-	-	4.1	-	2.9	-	4.1	-	-	-	4.6	
263	-	-	-	83.1	-	78.7	-	79.3	-	-	-	81.1	
264	-	-	-	10.5	-	14.4	-	13.4	-	-	-	12.0	
265	-	-	-	1.6	-	3.6	-	2.4	-	-	-	1.8	
300	-	-	-	-	-	-	-	-	-	-	85.5	-	
301	-	-	-	-	-	-	-	-	-	-	12.9	-	
302	-	-	-	-	-	-	-	-	0.4	1.6	-	0.5	
303	-	-	-	-	-	-	-	-	4.1	-	-	4.6	
304	-	-	-	-	-	-	-	-	81.0	-	-	81.1	
305	-	-	-	-	-	-	-	-	12.5	-	-	12.0	
306	-	-	-	-	-	-	-	-	2.0	-	-	1.8	

10 pmol PA or d₄PA-monosaccharide was injected

Table 2
内部標準単糖を用いた GCC-LC/MS による d₀-PA-単糖分析の再現性(RSD)

	d ₀ -PA-monosaccharides (pmol)								
	0.05			0.5			5		
	IS(-)	IS(A)	IS(B)	IS(-)	IS(A)	IS(B)	IS(-)	IS(A)	IS(B)
Gal	16.2	15.5	5.7	11.6	8.3	2.1	5.0	5.5	2.3
Man	12.7	15.3	4.7	9.7	7.1	1.8	7.2	4.6	1.7
Glc	12.9	17.5	3.9	8.9	7.6	4.8	10.9	5.1	1.1
Fuc	23.9	17.3	4.2	9.9	7.6	1.9	5.4	6.1	0.8
GlcNAc	15.2	7.7	3.5	9.0	5.6	2.0	5.4	6.0	1.2
GalNAc	16.0	21.0	9.4	11.4	7.4	4.7	9.8	3.5	1.5

Note. n=5. IS, internal standard. A, PA-rhamnose; B, d₄-PA-monosaccharides.

Table 3
内部標準単糖を用いた GCC-LC/MS による単糖組成分析

Glycoprotein	Monosaccharide	mol/mol ^a	mol/mol
Fetuin	Fuc	0.3	0 ^b
	Gal	10.4	12
	Man	7.6	9
	GlcNAc	14.7	15
	GalNAc	3.4	3
Erythropoietin	Fuc	3.4	4.1 ^c
	Gal	12.8	13.8
	Man	8.1	8.7
	GlcNAc	15.6	17.2
	GalNAc	1.5	0.9

^aValues were expressed as mol detected in 1 mol glycoprotein. ^bRef, *Anal. Biochem.* 197, (1991) 132-136; ^cRef, *J. Biol. Chem.* 262 (1987) 12059-12076




Fig. 3 安定同位体標識単糖及びGCC-LC/MSを用いた単糖分析法の定量性




Fig. 4 フェツイン(A)及びエリスロポエチン(B)の単糖組成分析
 マスクロマトグラム m/z 243 (1), 247 (2), 259 (3), 263 (4), 300 (5), 304 (6)




Fig. 5 hCG由来 d_4 -PA化アシアロ2本鎖糖鎖のGCC-LC/MS

(A), (A'), マスクロマトグラム; ピーク a, a' のマススペクトル (B), (B')
 (A), (B), positive ion mode; (A'), (B'), negative ion mode




Fig. 6 PA化hCG由来糖鎖のプロファイル

(A), d_4 -PA hCG 及び d_0 -PA rhCG 混合物のTIC; (B), d_4 -PA hCGのTIC; (C), d_0 -PA rhCG のTIC




Fig. 7 d₀-PA rhCG 及び d₄-PA hCG 混合物のTICの2D表示




Fig. 8-1 Fig. 7中のピーク a~s のマススペクトル




Fig. 8-2 つづき




Fig. 8-3 つづき




Fig. 8-4 つづき




Fig. 8-5 つづき

Table 4 Fig. 7 で検出されたピーク a-s の帰属

Peak No.	Carbohydrate composition	Deduced structure	Theoretical mass (d ₀ PA-sugar)	Observed m/z		
				d ₀ -PA rhCG		d ₄ -PA hCG
				M ²⁻	M ³⁻	M ²⁻
a1	[Hex] ₅ [HexNAc] ₃	Hybrid(1)	1517.5	757.5		759.5
b1	[Hex] ₅ [HexNAc] ₄ [NeuNAc] ₂	Bi(1)NA ₂	2303.1		768.2	
c1	[Fuc] ₁ [Hex] ₅ [HexNAc] ₄ [NeuNAc] ₂	FBi(1)NA ₂	2449.3		816.7	
d1	[Hex] ₄ [HexNAc] ₃ [NeuNAc] ₁	Mono(1)NA	1646.6			824.3
d2	[Hex] ₄ [HexNAc] ₃ [NeuNAc] ₁	Mono(1)NA	1646.6			824.0
e1	[Hex] ₆ [HexNAc] ₃	Hybrid(2)	1679.6	838.6		
f1	[Hex] ₆ [HexNAc] ₃	Hybrid(2)	1679.6			840.6
g1	[Hex] ₅ [HexNAc] ₄	Bi(1)	1720.7	858.9		
h1	[Hex] ₅ [HexNAc] ₄	Bi(1)	1720.7			861.2
i1	[Hex] ₅ [HexNAc] ₃ [NeuNAc] ₁	Hybrid(1)NA	1807.7	902.9		
i2	[Hex] ₅ [HexNAc] ₃ [NeuNAc] ₁	Hybrid(1)NA	1808.7			905.0
j1	[Fuc] ₁ [Hex] ₅ [HexNAc] ₄	FBi(1)	1866.8			934.0
k1	[Hex] ₆ [HexNAc] ₄	Hybrid(3)	1882.8	940.2		
l1	[Hex] ₅ [HexNAc] ₅	Bi(1)-GN	1924.9			962.7
m1	[Hex] ₆ [HexNAc] ₃ [NeuNAc] ₁	Hybrid(2)NA	1970.8			986.8
m2	[Hex] ₆ [HexNAc] ₃ [NeuNAc] ₁	Hybrid(2)NA	1970.8			986.2
n1	[Hex] ₅ [HexNAc] ₄ [NeuNAc] ₁	Bi(1)NA	2011.9	1004.7		1006.7
n2	[Hex] ₅ [HexNAc] ₄ [NeuNAc] ₁	Bi(1)NA	2011.9	1004.6		1007.3
n3	[Hex] ₅ [HexNAc] ₄ [NeuNAc] ₁	Bi(1)NA	2011.9	1004.6		
n4	[Hex] ₅ [HexNAc] ₄ [NeuNAc] ₁	Bi(1)NA	2011.9	1004.6		1006.5
n5	[Hex] ₅ [HexNAc] ₄ [NeuNAc] ₁	Bi(1)NA	2011.9	1004.6		1006.4
o1	[Hex] ₇ [HexNAc] ₄	Hybrid(4)	2044.9	1021.4		
p1	[Fuc] ₁ [Hex] ₅ [HexNAc] ₄ [NeuNAc] ₁	FBi(1)NA	2158.0			1079.8
p2	[Fuc] ₁ [Hex] ₅ [HexNAc] ₄ [NeuNAc] ₁	FBi(1)NA	2158.0			1079.8
p3	[Fuc] ₁ [Hex] ₅ [HexNAc] ₄ [NeuNAc] ₁	FBi(1)NA	2158.0			1079.8
q1	[Hex] ₆ [HexNAc] ₄ [NeuNAc] ₁	Hybrid(3)NA	2174.0	1085.6		
q2	[Hex] ₆ [HexNAc] ₄ [NeuNAc] ₁	Hybrid(3)NA	2174.0	1085.7		
r1	[Hex] ₅ [HexNAc] ₄ [NeuNAc] ₂	Bi(1)NA ₂	2303.1	1150.3		1152.1
r2	[Hex] ₅ [HexNAc] ₄ [NeuNAc] ₂	Bi(1)NA ₂	2303.1	1150.2		1152.2
r3	[Hex] ₅ [HexNAc] ₄ [NeuNAc] ₂	Bi(1)NA ₂	2303.1	1150.1		
r4	[Hex] ₅ [HexNAc] ₄ [NeuNAc] ₂	Bi(1)NA ₂	2303.1	1150.3		1152.4
s1	[Fuc] ₁ [Hex] ₅ [HexNAc] ₄ [NeuNAc] ₂	FBi(1)NA ₂	2449.3			1225.4

Hex: hexose, HexNAc: *N*-acetyl hexosamine, NeuNAc, NA: *N*-acetyl neuraminic acid, Fuc, F: fucose, mono: monoantennary, bi: biantennary, GN: bisecting GlcNAc

Table 5 Table 4 に示した糖鎖の推定構造

Abbreviation	Structure ^a	Theoretical mass ^b
Hybrid(1)	$\begin{array}{c} \text{Man—Man} \\ \diagdown \quad \diagup \\ \text{Gal—GlcNAc—Man} \end{array} \text{—Man—GlcNAc—GlcNAcOH}$	1440.3
Hybrid(2)	$\begin{array}{c} \text{Man} \\ \diagdown \quad \diagup \\ \text{Man—Man} \\ \diagdown \quad \diagup \\ \text{Gal—GlcNAc—Man} \end{array} \text{—Man—GlcNAc—GlcNAcOH}$	1602.5
Hybrid(3)	$\begin{array}{c} \text{Man—Man} \\ \diagdown \quad \diagup \\ \text{Gal—GlcNAc—Man} \\ \diagdown \quad \diagup \\ \text{Gal—GlcNAc—Man} \end{array} \text{—Man—GlcNAc—GlcNAcOH}$	1440.3
Hybrid(4)	$\begin{array}{c} \text{Man} \\ \diagdown \quad \diagup \\ \text{Man—Man} \\ \diagdown \quad \diagup \\ \text{Gal—GlcNAc—Man} \\ \diagdown \quad \diagup \\ \text{Gal—GlcNAc—Man} \end{array} \text{—Man—GlcNAc—GlcNAcOH}$	1805.6
Mono(1)	$\begin{array}{c} \text{Man} \\ \diagdown \quad \diagup \\ \text{Gal—GlcNAc—Man} \end{array} \text{—Man—GlcNAc—GlcNAcOH}$	1278.2
Bi(1)	$\begin{array}{c} \text{Gal—GlcNAc—Man} \\ \diagdown \quad \diagup \\ \text{Gal—GlcNAc—Man} \end{array} \text{—Man—GlcNAc—GlcNAcOH}$	1643.5
Bi(1)-GN	$\begin{array}{c} \text{Gal—GlcNAc—Man} \\ \diagdown \quad \diagup \\ \text{Gal—GlcNAc—Man} \end{array} \begin{array}{c} \text{GlcNAc} \\ \\ \text{Man—GlcNAc—GlcNAcOH} \end{array}$	1846.7
FBi(1)	$\begin{array}{c} \text{Gal—GlcNAc—Man} \\ \diagdown \quad \diagup \\ \text{Gal—GlcNAc—Man} \end{array} \text{—Man—GlcNAc—} \begin{array}{c} \text{Fuc} \\ \\ \text{GlcNAcOH} \end{array}$	1789.7

^a Man, mannose; Fuc, fucose; Gal, galactose; GlcNAc, *N*-acetylglucosamine.

The structure are based upon the known structure of hCG.

^b Average mass value.







Fig. 9 rhCG及びhCGに共通して結合している糖鎖の相対結合比

(A) mono-, (B) di-sialylated biantennary


Man7/D1 :




Man7/D3 :



Tri :



TriNA₃ :



TetraNA₄ :




Fig. 10 モデル糖鎖の構造




Fig.11 GCC-LC/liner ITMS-FT ICRMSによるモデル糖鎖のプロファイリング
 (A) 溶出時間 vs m/z 値、(B) 溶出時間 vs m/z 値 vs イオン強度




Fig. 12 高マンノース型糖鎖のプロダクトイオンスペクトル





Fig. 13 シアロ糖鎖のプロダクトイオンスペクトル




Fig. 14 ラット脳膜由来可溶性GPIアンカー型タンパク質のSDS-PAGE